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membranes, the polyclonal antibody recognizes a single protein band that is somewhat larger ( by Ç30 kD ) than the molecular This study uses immunostaining techniques to obtain eviweight of the rat receptor. Moreover, the monoclonal ( but not dence for the presence of presynaptic NMDA receptors in the polyclonal ) antibody abolishes the physiological effect of crayfish axon terminals. Because specific antibodies for cray-NMDA on glutamate release. The monoclonal antibody did not fish NMDA receptors are not available, we tried two antibodprevent the presynaptic effects of glutamate, which also reduces ies (available commercially) raised against the mammalian release by activation of quisqualate presynaptic receptors. Only NMDA receptor. Although the two receptors have different when 6-cyano-7-nitroquinoxatine-2,3,dione ( CNQX ) was added physiological properties, they may have retained some structogether with the monoclonal antibody was the presynaptic effect tural similarity because in many cases channels and receptors of glutamate blocked. These results show that presynaptic glutamate receptors of the crayfish NMDA type are involved in the evolved each from a common ancestor (Hille 1992) . Such an regulation of neurotransmitter release in crayfish axon terminals. assumption gains support from the finding of some structural Although the crayfish receptor differs in its properties from the similarity between the NMDA receptor of arthropods ( Dromammalian NMDA receptor, the two receptors retained some sophila) and the mammalian NMDA receptors (Ultsch et structural similarity. al. 1993) .
One of the antibodies is an anti-NMDA receptor subunit 1 (NMDAR1), monoclonal antibody (mAb) (Siegel et al. 
I N T R O D U C T I O N 1994
). The other is a polycloncal antibody (pAb) raised Glutamate receptors of the N-methyl-D-aspartate against splice variants NR1-1a, NR1-1b, NR1-2a, and (NMDA) type are involved in long-term synaptic modula-NR1-2b of NMDAR1 (Petralia et al. 1994) . tion in the mammalian brain (Bliss and Collingridge 1993;  By electron microscopy, we identified positive immuno- Collingridge and Singer 1990; Mulkey and Malenka 1992) . staining for NMDA receptors on the presynaptic membrane Such NMDA receptors were thought to exist only in verte-of crayfish release boutons. Staining was not found on musbrates (Mayer and Westbrook 1987) , but evidence suggests cle or nonneuronal elements. We further show by Western that NMDA acts also in invertebrates (Dale and Kandel analysis that the pAb recognizes a single protein band that 1993; Evans et al. 1992; Parnas et al. , 1996 ; Pfeiffer-is somewhat larger (by Ç30 kD) than the mammalian Linn and Glantz 1991; Ultsch et al. 1993) . Recently, it was NMDAR1. Moreover, the mAb (but not the polyclonal antishown that NMDA reduces release of transmitter from cray-body) completely abolished the physiological effect of fish terminals at concentrations as low as 10 07 M (Parnas et NMDA. The mAb did not block the physiological effects of al. 1996). These crayfish NMDA receptors whose activation glutamate that also acts via quisqualate presynaptic receptors affects-directly or indirectly-the release of transmitter (Parnas et al. 1996) . To abolish the presynaptic effect of differ in their physiological properties from the mammalian glutamate the combined action of the mAb together with 6-NMDA receptor. Their activation is not associated with an cyano-7-nitroquinoxaline-2,3,dione (CNQX) was required. increase in membrane conductance, there is no increase in
Our results indicate that, in the crayfish, feedback inhibiintracellular Ca 2/ concentration, and a change in extracellu-tion of glutamate release is mediated, in part, by crayfish NMDA receptors located on presynaptic axon terminals. AlThe costs of publication of this article were defrayed in part by the though these receptors differ in their properties from the payment of page charges. The article must therefore be hereby marked mammalian receptor, the two receptors (crayfish and mam-''advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ment was then incubated in 5, 15, or 50 mg/ml anti-NMDAR1 Here we used the rapid application technique developed by Dusee Parnas et al. , 1996 . Abdominal ganglia of P. clarkii del (1989) . A thin tube was inserted into the macropatch electrode were used for Western blots. To obtain the abdominal ganglia, we as close as possible to the tip (see Fig. 1 in Dudel et al. 1993) . separated the abdomen of the crayfish from the cephalothorax. The This tube was connected via a switch to two reservoirs, one concephalothorax was then rapidly crushed. The abdominal ganglia taining VH solution and the other containing NMDA or glutamate were then isolated for the Western blots. As a control for Ab solution. This allowed us to change the fluid in the electrode rapidly binding, we used rat brains. Male Sprague-Dawley rats, 180-200 and to superfuse only the region below the electrode tip (for technig, were killed by CO 2 inhalation in accordance with guidelines set cal details see Parnas et al. 1996) . forth by the National Institutes of Health.
Once the macropatch electrode was positioned over a release bouton, we depolarized the bouton with pulses of 1-ms duration
Western blotting
and an amplitude of 00.4 mA. Because the blocking effect of NMDA or glutamate depends on the amplitude of the depolarizing Crayfish abdominal ganglia, crayfish DEAM muscles, and rat pulse (Parnas et al. 1996) , we needed to select depolarizing pulses brain tissue were each homogenized in a glass homogenizer in low enough to allow the blocking effect of NMDA or glutamate Krebs buffer supplemented with protease inhibitors (4-2-amino to occur, yet high enough to yield measurable quantal content (see ethylbenzenesulfonyl fluoride, 1 mM; aprotinin, 1 mg/ml; leupep- Fig. 1 in Parnas et al. 1996) . Quantal content was first determined tin, 5 mg/ml). Nuclei were precipitated (350g, 15 min, 4ЊC), and when the site was superfused with VH solution (control). Four to the resulting supernatant was centrifuged at 300,000g for 20 min five series of 256 pulses at 5 Hz were administered to establish at 4ЊC. The membranous fraction (pellet) was resuspended in soluquantal content (Fig. 5A ). When the quantal content became stabilization buffer (1% Triton X-100, 150 mM NaCl, 25 mM Tris, ble, i.e., varied õ20% between points, we switched to a perfusion pH 8), and the supernatant was precipitated with 80% acetone.
fluid containing 10 06 M NMDA or 10 06 M glutamate. Quantal Protein concentration was determined by the microBCA method content was then monitored continuously for a series of 256 pulses, (Pierce, Rockford, IL). Thirty milligrams of protein from each until it had fallen to õ50% of the control or stabilized at a steady fraction was analyzed by sodium dodecyl sulfate-polyacrylamide level of inhibition. Finally, the site was washed again with VH gel electrophoresis on a 10% gel. The pAb antibody (Chemicon solution to test for recovery. International, Temecula, CA) was diluted 1:50. Detection was by enhanced chemiluminescence.
Calculation of quantal content Electrophysiological measurements
Single quanta events are clearly distinguishable at 12ЊC (see Fig. 5 ). Counting the number of quanta and dividing by the number Electrophysiological measurements were carried out as deof pulses provides a direct measure of quantal content. The quanscribed by Parnas et al. ( , 1996 . Briefly, single quanta events tum size measured was not influenced by postsynaptic effects, as were recorded extracellularly by means of the macropatch focal there are no postsynaptic NMDA receptors in the DEAM, and the recording technique (Dudel 1981) . The same macropatch electrode concentration of glutamate used here (1 1 10 06 M) does not cause (12-mm opening) was used to depolarize a single, or at most two, appreciable desensitization (Parnas et al. , 1996 . Recordings release boutons (Fischer and Parnas 1996) as well as to record were digitized at 50 KHz (LabVIEW interface, National Instruquantal responses. Samples of such recordings are shown in Fig. ments, Austin, TX) and analyzed with a Pentium computer. In the 5. The preparation was treated with 5 1 10 07 M tetrodotoxin. The crayfish, synapses on the same muscle show large differences in depolarizing pulse was 1 ms, 00.4 mA. The temperature was quantal content (Cooper et al. 1995; Parnas et al. 1996) . For this 11-12ЊC.
reason, and to present observations from different synapses together, we normalized our results, presenting quantal content as a
Testing for the effects of antibodies
percentage of the control at each site. To give the antibodies ample time to reach the presynaptic release boutons, the preparation was incubated for ¢2 h with the Prefixation immunogold staining antibody. Because of the long incubation period and the relatively larger volumes required to perfuse a bouton through the macropatch Because we found that incubation of the live preparation with the mAb blocks the physiological effect of NMDA, we assumed that the electrode (Dudel 1989 ), we could not perform the antibody-treated and -untreated experiments while recording from the same release antibody binds with the receptor under these conditions. We therefore exposed the muscle hemisegments to the primary and secondary antisite as in previous experiments (Parnas et al. , 1996 . Instead, the left and right hemisegments containing only the L 1 and L 2 bodies before any fixation procedure and consequently without any permeabilization of the membranes. As shown, this approach was muscles of the DEAM (Parnas and Atwood 1966) were isolated. One hemisegment from each segment served as the untreated con-found successful for both antibodies. The live preparation was incubated at room temperature for 1 h in VH solution containing 2% BSA trol, and the second hemisegment was treated with the antibody. Each hemisegment was first incubated for 1 h in Van Harreveld for the mAb or in 5% NGS for the pAb. The muscle was then transferred to VH solution containing 15 mg/ml mAb anti-NMDAR1 (VH) solution (0.5 ml) containing either 2% bovine serum albumin (BSA) for the mAb or 5% normal goat serum (NGS) for the pAb. or 5 mg/ml pAb for ¢2 h. Then the preparation was washed several times in VH solution and transferred to the proper secondary antibody This solution served as a blocking solution. One hemisegment was then incubated with 50 mg/ml mouse preimmune serum (for the for 2 h. Subsequently, the hemisegments were incubated in IgG (Fab fragment) coupled to 1.4 nm gold (Nanoprobes, Stonybrook, NY). mAb) for ¢2 h, followed by washings with VH solution and taken as an ''untreated'' hemisegment. The second, ''treated'' hemiseg-After this incubation, the muscle specimens were washed several J285-8 / 9k2f$$de50
12-01-98 12:48:07 neupa LP-Neurophys boutons (multiterminal innervation) (Atwood 1977). Many of these release boutons are embedded in dimples in the muscle fiber (Fig. 1 ). Each release bouton or varicosity contains several release sites (Wojtowicz et al. 1994) . Figure 1 shows that the postsynaptic membrane is at some distance from the myofibrils, and the peripheral extrafibrilar sarcoplasm is occupied by large mitochondria and other sarcoplasmic elements. In Fig. 1 Intense staining with the pAb was obtained with the silverpostsynaptic (po) membranes are clearly visible. The peripheral extrafibrilar enhanced method (Fig. 2) . In many cases, there was a clear sarcoplasm is occupied by large mitochondria (mi). Scale bar, 0.5 mm.
distinction between the pre-and the postsynaptic membranes, and clusters of particles were visible in the presynaptimes in VH solution and fixed overnight at 4ЊC in 0.2 M cacodylate buffer, pH 7.4 containing 4% glutaraldehyde. The specimens were tic membranes (Fig. 2) . then transferred to cacodylate buffer. The muscle specimens were Five animals were used for the staining with the pAb. washed in double-distilled water and were then silver enhanced with Nine hemisegments were taken, and in these we found 51 an HQ silver kit (Nanoprobes) (Lujan et al. 1996) . After this proce-stained terminals with 94 presynaptic clusters. For method specifity we run several controls in which the pri-tures. We used 6 animals with 11 hemisegments for the mAb. mary antibody was substituted as follows: 1) omitting the primary In 34 terminals, we found staining with mAb, containing 44 Ab, 2) incubation with preimmune serum, and 3) incubation with clusters.
an irrelevant monoclonal Ab antineurophysin (Ben-Barak et al. 1985) . In none of these controls did we find any labeling on Western analysis presynaptic terminals or any other nonneuronal membranes.
Because the mass of muscle tissue and its membranes was R E S U L T S much larger than the membranes of the embedded small Antibodies for NMDAR1 stain axon terminals release boutons, we performed Western analysis on crayfish ganglia, which are rich in synaptic connections and were In the crayfish neuromuscular system, axon terminals run and bifurcate over the muscle fiber to form many release also immunostained by the mAb and pAb (not shown). We 
used crayfish muscles as controls and compared the results
The detection of a single band by the pAb together with the immunostaining with both antibodies demonstrate the with those obtained with rat brain. In each preparation, we compared the staining in the membranal and soluble frac-presence of presynaptic receptors that interact with NMDA in the crayfish axon terminals. It seems that a part of the tions.
By using the pAb, a single band of Ç150 kD was detected receptor molecule was conserved during evolution and that the two receptors (crayfish and mammalian) have some in the membranous fraction of the crayfish ganglia (cfgp) (Fig. 4) . The response was very specific, as staining was structural similarity. The two receptors are certainly not identical, as the crayfish NMDA receptor is somewhat larger not observed in the soluble fraction of the ganglia (cfgs) or in the two fractions of the crayfish muscle (cfm). The (by Ç30 kD) and has different physiological properties (Parnas et al. 1996) . membranous fraction of rat brain (rbp) showed intense staining, and as expected the soluble fractions showed no staining.
The mAb abolishes the physiological effects of NMDA Similar experiments with the mAb were not successful.
Antiglutamate receptor antibodies were used previously No detectable bands were observed in the crayfish membrane for physiological studies. For example, Shigemoto et al. fractions when the mAb was used. This may have resulted (1994) demonstrated that an antimetabotropic glutamate refrom the more sporadic binding of the mAb as seen with ceptor, anti-mGluR1 polyclonal antibody, blocked the inducthe immunogold staining (Fig. 3) .
tion of long-term depression of glutamate-induced currents in cultured rat Purkinje cells. We tested whether the polyclonal and monoclonal antibodies block the physiological effects of NMDA. Figure 5 shows the effects of NMDA on release in treated and untreated muscles. The traces in the top right column show sample recordings. One trace shows a failure in release, and the other two show one and two quanta. Figure 5A shows results obtained in eight synapses from a hemisegment incubated in BSA (3 preparations were also incubated with the preimmune mouse serum). Note that, in all eight synapses, after addition of 10 06 M NMDA (down arrow), quantal content declined to values õ50% of the control (before addition of the NMDA). After the preparations were washed (up arrow), quantal content continued to decline for two to three points and then recovered. These results are similar to those obtained by Parnas et al. (1996) in muscles that underwent no treatment. This indicates that the BSA, like the NGS and the mouse preimmune serum (important as a control for the mAb effects), did not affect the ability of NMDA to reduce release. We recorded from a total of 26 synapses from 5 muscles without antibodies (pooled re- cles not treated with antibody, addition of 10 06 M NMDA reduced quantal content with good recovery after washing. We tested the effect of NMDA on 16 synapses from pAbtreated muscles. Quantal content was always reduced by ú50%, with complete recovery after washing of the NMDA. Similar results were obtained in eight synapses in a hemisegment treated with 5 mg/ml pAb. Thus, at these concentrations, the polyclonal antibody did not block the presynaptic effects of 10 06 M NMDA. A different result was obtained in synapses from the mAbtreated muscles (Fig. 5C) . We tested hemisegments incubated with 5-, 15-, and 50-mg/ml mAb solutions. Synapses from hemisegments treated with 5 mg/ml mAb remained sensitive to 10 06 M NMDA. Quantal content declined in a manner similar to that shown in Fig. 5, A and B . In eight such synapses, release was reduced to levels 50% lower than the control, with recovery after washing (not shown). When other hemisegments were incubated with 15 mg/ml (same batch of mAb), application of 10 06 M NMDA was ineffective in reducing quantal content. Figure 5C shows results of eight such experiments. It is clear that quantal content fluctuated around the control level even after NMDA was added. In preparations washed for very long periods of ú2 h after removal of the antibody, NMDA was still ineffective; the blocking effect of the mAb was irreversible. Similar results were obtained from muscles treated with 50 mg/ml mAb. We tested the effect of NMDA on a total of 23 synapses from mAb-treated hemisegments (8 from muscles treated with 15 mg/ml and 15 from muscles treated with 50 mg/ml). Only in 2 of 15 synapses from hemisegments treated with 50 mg/ml mAb did 10 06 M NMDA reduce release. In the other 21 synapses, 10 06 M NMDA was ineffective in reducing release.
These results show that synapses from hemisegments treated with BSA / preimmune serum, NGS, and pAb (the hemisegments were incubated for the same period of time The finding that the mAb stains presynaptic terminals and hemisegments treated with BSA and then with 15 mg/ml mAb. Down arrow: also blocks the physiological effect of NMDA suggests that addition of 10 06 M glutamate as the agonist. Up arrow: washing with normal VH solution. E: results from hemisegment treated with 15 mg/ml the effect is specific. However, these results do not exclude mAb. In these experiments, the circulating fluid also contained 10 05 M 6-the possiblity that the mAb raised against the mammalian cyano-7-nitroquinoxatine-2,3,dione. The agonist was glutamate, 10
06 M. NMDA receptors may also bind to other glutamate receptor Symbols as described previously.
types in crayfish axon terminals. It was therefore necessary to test whether the mAb blocks the physiological effect of glutamate. pAb. The hemisegments were treated with 5-, 15-, or 50-mg/ml solutions. The recordings from muscles treated with Figure 5D shows that, for hemisegments incubated with 15 mg/ml mAb, the quantal content declined after addition 50 mg/ml deteriorated rapidly. We therefore limited our measurements to hemisegments treated with 5 or 15 mg/ml and of 10 06 M glutamate, with recovery after washing. Similar results were obtained in hemisegments treated with 50 mg/ did not investigate further the problem of deterioration. Figure 5B shows the quantal content obtained in eight synapses ml mAb (12 synapses from 3 hemisegments; not shown).
It should be emphasized that 10
06
M NMDA did not reduce from a hemisegment treated with 15 mg/ml pAb. As in mus-release in synapses of hemisegments where glutamate did. several minutes to establish the effect and ú20 min to recover after washing (Parnas et al. , 1996 . Second, the This suggests that, whereas the NMDA type receptors were blocked by the mAb, the quisqualate type receptors were pAb was reported to be raised against an internal domain of the mammalian receptor (Petralia et al. 1994 ). Nevertheless, not. These results resemble those obtained in muscles incubated with APV. There too, the effect of NMDA, but not this pAb immunostained crayfish terminals while exposing them to the antibody without permeabilization of the memthat of glutamat, was blocked by APV (Parnas et al. 1996) .
We therefore expected that application of CNQX together brane. This means that the pAb recognized an extracellular domain or domains. Binding to these domains did not, howwith mAb would render the synapses insensitive to glutamate, and this indeed is what occurred (Fig. 5E) . Here the ever, block the physiological activity of NMDA. It is possible that the crayfish receptor, which has different physiologihemisegments were incubated with 15 mg/ml mAb. The fluid circulating during the electrophysiological measurements in-cal properties, also differs somewhat in its structure from the mammalian receptor. This possibility is strengthened by cluded 10 05 M CNQX. Under these conditions, 10 06 M glutamate (down arrow) did not reduce quantal content (6 the finding that the crayfish receptor is larger. With respect to the mAb, the physiological results agree with current synapses).
The findings that 15 mg/ml mAb completely abolished views concerning the recognition site. The mAb was thought to recognize an intracellular loop between transmembrane the physiological effect of 10 06 M NMDA, but not that of 10 06 M glutamate, and that even 50 mg/ml mAb did not regions III and IV (Hollman et al. 1989; Keinänen et al. 1990; see Hollmann and Heinemann 1994) . However, it has abolish the blocking effect of glutamate further reduces the likelihood that the effect of the mAb is nonspecific. The been shown (Hollman et al. 1994 ) that this domain is external in the ionotropic non-NMDA receptor (GluR1). Because additional finding that the mAb applied together with CNQX did block the effect of glutamate reinforces earlier indica-the NMDA receptor has a similar structure (Moriyoshi et al. 1991) , it is possible that this domain is external in the tions (Parnas et al. 1996 ) that these two types of crayfish presynaptic glutamate autoreceptors, an NMDA receptor and crayfish receptor as well.
The physiological effect of the mAb was specific for a non-NMDA receptor, are involved in the feedback inhibition of release.
NMDA. It did not block the effect of glutamate, which also activates quisqualate receptors. This indicates that in the crayfish there are fundamental differences in the structure D I S C U S S I O N of the receptor that binds NMDA and the one that binds quisqualate. We investigated whether the effect of NMDA on glutamate release in the crayfish is achieved by directly activating Presynaptic NMDA receptors were found in the presynaptic terminals of mammals. Such receptors were found in an NMDA-type receptor located on the presynaptic excitatory terminals.
the spinal cord (Liu et al. 1994) , and recently, Conti and colleagues (Conti et al. 1997; Debiasi et al. 1996) identified The finding that the effect of NMDA and glutamate on release depends on the amplitude of the depolarizing pulse presynaptic NMDA receptors in the cerebellar cortex, with the same polyclonal antibody. The physiological role of the (Parnas et al. , 1996 demands that the presynaptic glutamate receptors reside in the presynaptic membrane. presynaptic NMDA receptors in mammals is not known. It is possible that in mammals, as in crayfish, they are involved Otherwise, how could they be affected by the invading action potential? Our results show that the NMDA-type receptor is in inhibition of release of glutamate from nerve terminals. indeed located on presynaptic nerve terminals.
Because we did not find any evidence that NMDA-type This work was supported by a grant from the Deutsche Forschungsgereceptors are located on the muscle or glial cell membranes, meinschaft, SFB 391, Germany. We thank the Anna Lea Foundation for its continuous support. I. Parnas is the Greenfield Professor of Neurobiology.
the possiblity that glutamate inhibits its own release by indirect action is less likely.
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